dostarlimab,pembrolizumab
gsk,merck
['nsclc', 'sclc', 'gi ', 'dostarlimab', 'perla trial', 'pembro', 'dostar ']
let the pd1 wars begin! #esmoimmuno22 dostarlimab seems not only non-inferior, but trends for superiority vs pembro, with ct in nsclc 1l. supported by trend increasing with hi pdl1. not only a metoo drug then... what is the "perfect" anti-pd1? 
Oncologist, clinician scientist, failed drummer, accomplished father